Are Bcr-Abl KD mutations already detectable at the time ... - siesonline

More documents

Recommendations

Info

Patients (I)→ RNA samples collected at the time of diagnosis from13 patients enrolled on a phase II study of the treatmentof adult de novo Ph+ ALL with dasatinib (GIMEMA LAL1205)DASATINIB 70 mg BIDPDNi.t. mtxi.t. mtx-6 0 +1 +22 +32 +43+84 days
Patients (II)NSexAgeBcr-Abl typeStatus (time fromthe start of dasatinib,mo)Mutation atdiagnosis(direct seq)Mutation atrelapse(direct seq)1M49p190Relapsed (10)WTT315I2M56p210Relapsed (6)WTT315I3M56p210Relapsed (7)WTWT4F47p190Relapsed (4)WTWT5F74p210Relapsed (8)WTT315I6F58p210Relapsed (7)WTE255K7F59p210Relapsed (2)WTT315I8F30p210Relapsed (6)WTT315I9F57p190Remission (13)WTN.A.10F34p190Remission (5)WTN.A.11M52p190Remission (12)WTN.A.12F73p210Remission (23)WTN.A.13M72p190Remission (20)WTN.A.N.A., not applicable
Page 1 and 2: LAL:significato clinico e biologico
Page 3 and 4: Imatinib-resistant pts with Ph+ ALL
Page 5 and 6: Second-line TKIs in imatinib resist
Page 7 and 8: In ALL genetic instability is high
Page 9: Are Bcr-Abl KD mutations alreadydet
Page 13 and 14: Results (I)Aberrant Bcr-Abl KD sequ
Page 15 and 16: N12345678910111213Status (time from
Page 17 and 18: Take-home messagesa) Bcr-Abl KD mut

Are Bcr-Abl KD mutations already detectable at the time ... - siesonline

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?